CA2212370A1 - Inhibition de l'angiogenese a l'aide de l'interleukine-12 - Google Patents

Inhibition de l'angiogenese a l'aide de l'interleukine-12

Info

Publication number
CA2212370A1
CA2212370A1 CA002212370A CA2212370A CA2212370A1 CA 2212370 A1 CA2212370 A1 CA 2212370A1 CA 002212370 A CA002212370 A CA 002212370A CA 2212370 A CA2212370 A CA 2212370A CA 2212370 A1 CA2212370 A1 CA 2212370A1
Authority
CA
Canada
Prior art keywords
angiogenesis
treatment
interleukin
mice
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002212370A
Other languages
English (en)
Inventor
Moses Judah Folkman
Gary Arthur Truitt
Emile Eugene Voest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Childrens Medical Center Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2212370A1 publication Critical patent/CA2212370A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation de l'interleukine-12 pour la préparation d'un médicament permettant de traiter l'angiogenèse indésirable ou non maîtrisée, ce qui est important pour le traitement de la rétinopathie diabétique et de la dégénérescence maculaire.
CA002212370A 1995-02-16 1996-02-07 Inhibition de l'angiogenese a l'aide de l'interleukine-12 Abandoned CA2212370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38938295A 1995-02-16 1995-02-16
US08/389,382 1995-02-16

Publications (1)

Publication Number Publication Date
CA2212370A1 true CA2212370A1 (fr) 1996-08-22

Family

ID=23538033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002212370A Abandoned CA2212370A1 (fr) 1995-02-16 1996-02-07 Inhibition de l'angiogenese a l'aide de l'interleukine-12

Country Status (8)

Country Link
EP (1) EP0809511A1 (fr)
JP (1) JPH11500119A (fr)
AU (1) AU4788396A (fr)
BR (1) BR9607427A (fr)
CA (1) CA2212370A1 (fr)
FI (1) FI973356A0 (fr)
TR (1) TR199700801T1 (fr)
WO (1) WO1996025171A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69722178T2 (de) * 1996-11-22 2003-11-27 Toray Industries Therapeutischer wirkstoff für augenerkrankungen
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
EP0986393B1 (fr) * 1997-05-27 2004-03-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
CA2308438A1 (fr) * 1997-11-03 1999-05-14 The Wistar Institute Of Anatomy And Biology Methode et compositions d'inhibition de l'angiogenese et de traitement du cancer
IL157713A0 (en) 2001-03-29 2004-03-28 Schering Corp Aryl oxime-piperazines useful as ccr5 antagonists
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106368A1 (fr) * 1992-01-16 1993-07-17 Theodore E. Maione Methodes et compositions pour le traitement de la maladie angiogenique
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法

Also Published As

Publication number Publication date
TR199700801T1 (xx) 1998-03-21
FI973356A (fi) 1997-08-15
JPH11500119A (ja) 1999-01-06
EP0809511A1 (fr) 1997-12-03
FI973356A0 (fi) 1997-08-15
WO1996025171A1 (fr) 1996-08-22
BR9607427A (pt) 1998-06-23
AU4788396A (en) 1996-09-04
MX9706188A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
EP0688211B1 (fr) Thalidomide pour inhiber l'angiogenese
USRE40360E1 (en) Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide
US6228879B1 (en) Methods and compositions for inhibition of angiogenesis
US20020161023A1 (en) Method of treating diseases using 3-amino thalidomide
CA2212370A1 (fr) Inhibition de l'angiogenese a l'aide de l'interleukine-12
US20120142734A1 (en) Methods for treating tumors with thalidomide
US6890906B2 (en) Method for controlling angiogenesis in animals
MXPA97006188A (en) Inhibition of angiogenesis using interleucin
US20020098176A1 (en) Inhibition of tumor growth by a nematode anticoagulant protein
CN1189102A (zh) 白细胞介素－12对血管生成的抑制作用

Legal Events

Date Code Title Description
FZDE Dead